Optimizing the Prediction of Depression Remission: A Longitudinal Machine Learning Approach.

Area of Science:

• Pharmacogenomics
• Clinical Psychiatry
• Computational Biology

Background:

• Accurate prediction of antidepressant treatment outcomes is crucial for complex clinical decisions.
• Repeated symptom severity assessments during treatment can enhance prognostic accuracy.
• Individualized treatment strategies are essential for managing depression effectively.

Purpose of the Study:

• To evaluate the utility of repeated symptom severity measures in predicting antidepressant treatment remission.
• To determine the optimal time point for incorporating longitudinal data to inform treatment modification decisions.
• To assess drug-specific predictive performance using escitalopram and nortriptyline.

Main Methods:

• Utilized data from 714 participants in the Genome-Based Therapeutic Drugs for Depression study.
• Employed growth curve modeling and topological data analysis to extract longitudinal descriptors from symptom severity data collected at weeks 0, 2, 4, and 6.
• Integrated demographic, clinical, genetic, and longitudinal symptom data to predict remission (Hamilton Rating Scale ≤ 7).

Main Results:

• Repeated assessments gradually improved predictive performance in a drug-specific manner.
• By week 4, predictive models achieved useful discrimination: AUC = 0.777 (nortriptyline), AUC = 0.807 (escitalopram), and AUC = 0.794 (combined).
• Longitudinal data significantly enhanced the prediction of treatment outcomes compared to baseline measures alone.

Conclusions:

• Repeated symptom assessments, starting from week 4 of treatment, can inform decisions about switching or modifying antidepressant therapies.
• This approach offers a data-driven method to optimize depression management and improve patient outcomes.
• The findings highlight the value of dynamic monitoring in personalized pharmacotherapy for depression.